Immunotherapy combo shows promise for rare childhood tumors
NCT ID NCT04416568
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 2 trial is testing two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with rare INI1-negative cancers that have come back or not responded to treatment. The study aims to see if the combination can shrink tumors or slow disease progression. About 45 participants with specific tumor types are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to
If this works, it could offer a new treatment option for children and young adults with rare INI1-negative cancers that have not responded to standard therapies.
What could go wrong
This is a small, early-phase study (45 participants) with no control group, so results may not apply broadly. Immunotherapy can cause serious side effects like inflammation of organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Healthcare of Atlanta-Egleston
Atlanta, Georgia, 30322, United States
-
Children's Healthcare of Atlanta-Scottish Rite
Atlanta, Georgia, 30342, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
UCSF Benioff Children's Hospital
San Francisco, California, 94158, United States